CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 220 enrolled
Drug / intervention
LCP-AtorFen +2 moredrug
Likely dose
LCP-AtorFen 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00504829
NCT00504829Phase 2Completed
CompareCT.gov

A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia

Veloxis Pharmaceuticals·interventional·Posted Jul 20, 2007·Updated Feb 17, 2020

In Brief

A Phase 2 clinical trial evaluating LCP-AtorFen, atorvastatin, and 1 other intervention for Dyslipidemia. Completed, enrolled 220 participants across 1 site.

Detailed Summary

The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 20, 2007
Enrollment StartJul 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.9 years ago

Interventions

LCP-AtorFendrug

40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia

atorvastatindrug

dyslipidemia and mixed dyslipidemia

fenofibratedrug

dyslipidemia and mixed dyslipidemia